74.05
-0.27 (-0.36%)
| Penutupan Terdahulu | 74.32 |
| Buka | 75.34 |
| Jumlah Dagangan | 561,523 |
| Purata Dagangan (3B) | 1,096,580 |
| Modal Pasaran | 6,430,595,072 |
| Harga / Jualan (P/S) | 650.22 |
| Harga / Buku (P/B) | 10.65 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 Aug 2026 |
| EPS Cair (TTM) | -3.06 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.06% |
| Nisbah Semasa (MRQ) | 8.06 |
| Aliran Tunai Operasi (OCF TTM) | -169.86 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -68.57 M |
| Pulangan Atas Aset (ROA TTM) | -25.34% |
| Pulangan Atas Ekuiti (ROE TTM) | -65.82% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Spyre Therapeutics, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | -2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -5.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 0.5 |
| Purata | -1.63 |
|
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 8.71% |
| % Dimiliki oleh Institusi | 106.07% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |